Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies

Current Opinion in Hematology

Volumn 23, Issue 4, 2016, Pages 402-409

  Juilland, Mélanie ^a   Thome, Margot ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

AP 1; CARD11; immunodeficiency; lymphoma; NF B

Indexed keywords

CARMA1 PROTEIN; MALT1 PROTEIN; MULTIPROTEIN COMPLEX; PROTEIN BCL 10; PROTEINASE; SCAFFOLD PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; BCL10 PROTEIN, HUMAN; CARD11 PROTEIN, HUMAN; CASPASE; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; GUANYLATE CYCLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALT1 PROTEIN, HUMAN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

BENTA SYNDROME; CARCINOGENESIS; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMAGENESIS; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REVIEW; SEZARY SYNDROME; T CELL LEUKEMIA; CELL TRANSFORMATION; HUMAN; LEUKEMIA, LYMPHOID; METABOLISM; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARD SIGNALING ADAPTOR PROTEINS; CASPASES; CELL TRANSFORMATION, NEOPLASTIC; GUANYLATE CYCLASE; HUMANS; LEUKEMIA, LYMPHOID; LYMPHOMA; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; NF-KAPPA B; PROTEIN BINDING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 84964727060     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000257     Document Type: Review

References (57)

1. Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM. From MALT lymphoma to the CBM signalosome: three decades of discovery. Cell Cycle 2011; 10: 2485-2496
2. Rueda D, Thome M. Phosphorylation of CARMA1: the link(er) to NF-kappaB activation. Immunity 2005; 23: 551-553
3. Qiao Q, Yang C, Zheng C. et al. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Mol Cell 2013; 51: 766-779
4. Jaworski M, Thome M. The paracaspase MALT1: biological function and potential for therapeutic inhibition. Cell Mol Life Sci 2016; 73: 459-473
5. Turvey SE, Durandy A, Fischer A. et al. The CARD11-BCL10-MALT1 (CBM) signalosome complex: stepping into the limelight of human primary immunodeficiency. J Allergy Clin Immunol 2014; 134: 276-284
6. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229-243
7. Lenz G, Davis RE, Ngo VN. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679
8. Compagno M, Lim WK, Grunn A. et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721
9. da Silva Almeida AC, Abate F, Khiabanian H. et al. The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet 2015; 47: 1465-1470
10. Wang L, Ni X, Covington KR. et al. Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 2015; 47: 1426-1434
11. Kataoka K, Nagata Y, Kitanaka A. et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 2015; 47: 1304-1315
12. Snow AL, Xiao W, Stinson JR. et al. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med 2012; 209: 2247-2261
13. Brohl AS, Stinson JR, Su HC. et al. Germline CARD11 mutation in a patient with severe congenital B cell lymphocytosis. J Clin Immunol 2014; 35: 32-46
14. Buchbinder D, Stinson JR, Nugent DJ. et al. Mild B-cell lymphocytosis in patients with a CARD11 C49Y mutation. J Allergy Clin Immunol 2015; 136: 819-821
15. Juilland M, Gonzalez M, Erdmann T. et al. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Blood 2016; 127: 1780-1789
16. Knies N, Alankus B, Weilemann A. et al. Lymphomagenic CARD11/BCL10
17. BlonskaM, Zhu Y, Chuang HH. et al. Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood 2015; 125: 981-991
18. Coornaert B, Baens M, Heyninck K. et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008; 9: 263-271
19. Hailfinger S, Nogai H, Pelzer C. et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci U S A 2011; 108: 14596-14601
20. Baens M, Bonsignore L, Somers R. et al. MALT1 auto-proteolysis is essential for NF-kappaB-dependent gene transcription in activated lymphocytes. PLoS One 2014; 9: e103774
21. Klein T, Fung SY, Renner F. et al. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-kappaB signalling. Nat Commun 2015; 6: 8777
22. Elton L, Carpentier I, Staal J. et al. MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-kappaB signaling. FEBS J 2015; 283: 403-412
23. Rebeaud F, Hailfinger S, Posevitz-Fejfar A. et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 2008; 9: 272-281
24. Staal J, Driege Y, Bekaert T. et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J 2011; 30: 1742-1752
25. Uehata T, Iwasaki H, Vandenbon A. et al. Malt1-induced cleavage of regnase-1 in CD4(θ) helper T cells regulates immune activation. Cell 2013; 153: 1036-1049
26. Jeltsch KM, Hu D, Brenner S. et al. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation. Nat Immunol 2014; 15: 1079-1089
27. Lenz G, Davis RE, Ngo VN. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679
28. Davis RE, Ngo VN, Lenz G. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92
29. Young RM, Wu T, Schmitz R. et al. Survival of human lymphoma cells requires B-cell receptor engagement by self-Antigens. Proc Natl Acad Sci U S A 2015; 112: 13447-13454
30. Zhang J, Grubor V, Love CL. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013; 110: 1398-1403
31. Morin RD, Mendez-Lago M, Mungall AJ. et al. Frequent mutation of histonemodifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303
32. Lohr JG, Stojanov P, Lawrence MS. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109: 3879-3884
33. Pasqualucci L, Trifonov V, Fabbri G. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830-837
34. Wilson WH, Young RM, Schmitz R. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21: 922-926
35. Rahal R, Frick M, Romero R. et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014; 20: 87-92
36. Hadzidimitriou A, Agathangelidis A, Darzentas N. et al. Is there a role for antigen selection in mantle cell lymphoma'. Immunogenetic support from a series of 807 cases. Blood 2011; 118: 3088-3095
37. Vicente-Duenas C, Fontan L, Gonzalez-Herrero I. et al. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad Sci U S A 2012; 109: 10534-10539
38. Li Z, Wang H, Xue L. et al. Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma. Blood 2009; 114: 4158-4168
39. Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 2014; 15: e517-e526
40. Vaque JP, Gomez-Lopez G, Monsalvez V. et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood 2014; 123: 2034-2043
41. Sommer K, Guo B, Pomerantz JL. et al. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 2005; 23: 561-574
42. Stein B, Baldwin AS Jr, Ballard DW. et al. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 1993; 12: 3879-3891
43. Keller ET, Wanagat J, Ershler WB. Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1996; 1: d340-d357
44. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868
45. Gaide O, Favier B, Legler DF. et al. CARMA1 is a critical lipid raft-Associated regulator of TCR-induced NF-kappa B activation. Nat Immunol 2002; 3: 836-843
46. Blonska M, Pappu BP, Matsumoto R. et al. The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity 2007; 26: 55-66
47. Rosebeck S, Madden L, Jin X. et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011; 331: 468-472
48. Nie Z, Du MQ, McAllister-Lucas LM. et al. Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma. Nat Commun 2015; 6: 5908
49. Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 2012; 12: 774-785
50. Shimizu Y, Taraborrelli L, Walczak H. Linear ubiquitination in immunity. Immunol Rev 2015; 266: 190-207
51. Yang Y, Schmitz R, Mitala J. et al. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Disc 2014; 4: 480-493
52. Hailfinger S, Schmitt A, Schulze-Osthoff K. The paracaspase MALT1 dampens NF-kappaB signaling by cleaving the LUBAC subunit HOIL-1. FEBS J 2015; 283: 400-402
53. Nagel D, Spranger S, Vincendeau M. et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 2012; 22: 825-837
54. Fontan L, Yang C, Kabaleeswaran V. et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012; 22: 812-824
55. Eitelhuber AC, Vosyka O, Nagel D. et al. Activity-based probes for detection of active MALT1 paracaspase in immune cells and lymphomas. Chem Biol 2015; 22: 129-138
56. Hachmann J, Edgington-Mitchell LE, Poreba M. et al. Probes to monitor activity of the paracaspase MALT1. Chem Biol 2015; 22: 139-147
57. Douanne T, Gavard J, Bide're N. The paracaspaseMALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling. J Cell Sci 2016. [Epub ahead of print]